Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Phase 3

Completed

• Conditions: Prostatic Neoplasms
• Interventions: Drug: Leuprolide Mesylate

• Registration Number: NCT02234115
• Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Brief Summary

The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.

Detailed Description

This is a multi-center, open-label, single-arm study conducted in 2 parts. Part I was established to provide a vanguard of the first 30 subjects who will have more frequent monitoring of their safety. If safety is established, the remainder of the subjects will be entered into the clinical study (i.e., Part II). All subjects will be males with advanced prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.

Study Timeline

• Study Start: 2014-08
• Study First Submitted: 2014-09-01
• Study First Submitted QC: 2014-09-04
• Study First Posted: 2014-09-09
• Primary Completion: 2016-08-30
• Study Completion: 2017-01-05
• Results First Submitted: 2018-02-13
• Results First Submitted QC: 2018-03-14
• Results First Posted: 2018-04-13
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-20
• Last Update Posted: 2019-03-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 137

Inclusion Criteria

1. Males aged ≥ 18 years old

2. Males with histologically confirmed carcinoma of the prostate

3. Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy

4. Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit

5. Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2

6. Life expectancy of at least 18 months

7. Laboratory values

   • Absolute neutrophil count ≥ 1,500 cells/µL
   • Platelets ≥ 100,000 cells/µL
   • Hemoglobin ≥ 10 gm/dL
   • Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
   • AST (SGOT) ≤ 2.5 × ULN
   • ALT (SGPT) ≤ 2.5 × ULN
   • Serum creatinine ≤ 1.5 mg/dL
   • Lipid profile within acceptable range according to investigator's judgment
   • HgbA1c within acceptable range according to investigator's judgment
   • Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
   • Serum glucose within acceptable range according to investigator's judgement
   • Urinalysis within normal range according to the investigator's judgment

8. Agree to use male contraceptive methods during study trial

9. Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol

10. All aspects of the protocol explained and written informed consent obtained

Exclusion Criteria

• Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
• Receipt of any vaccination (including influenza) within 4 weeks of Baseline
• History of blood donation within 2 months of Baseline
• History of anaphylaxis to any LH-RH analogues
• Receipt of any LHRH suppressive therapy within 6 months of Baseline
• Major surgery, including any prostatic surgery, within 4 weeks of Baseline
• History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases. Subjects at risk for spinal cord compression will be excluded.
• Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
• History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
• History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
• Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator
• History of drug and/or alcohol abuse within 6 months of Baseline
• Contraindication to leuprolide or an LHRH agonist as indicated on package labeling
• Use of 5-alpha reductase inhibitor within the last 6 months of Baseline
• History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed
• Use of systemic corticosteroids at a dose >10 mg/d or anti-androgens
• Use of any investigational agent within 4 weeks of Baseline
• Use of any over-the-counter (OTC) medication within 4 weeks of Baseline except for those listed in the permitted Concomitant Treatment section.
• Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Leuprolide Mesylate 50mg	Leuprolide Mesylate	All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.

Primary Outcome Measures

Name	Time	Method
Efficacy of Leuprolide Mesylate (LMIS 50mg)	baseline to 28 days, 28 days to 336 days	The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) following the first injection of LMIS 50 mg from Day 28 through Day 336 (remaining duration of the study).

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events (AEs)	336 days	Safety analysis was based on the safety information from the laboratory evaluations, AEs, and SAEs.

Trial Locations

Locations (29)

Idaho Urologic Institute - Meridian; 🇺🇸 Meridian, Idaho, United States

Carolina Urologic Research Center; 🇺🇸 Myrtle Beach, South Carolina, United States

China Medical University Hospital (CMUH); 🇨🇳 Taichung City, Taichung, Taiwan

National Cheng Kung University Hospital (NCKUH); 🇨🇳 Tainan City, Tainan, Taiwan

National Taiwan University Hospital (NTUH); 🇨🇳 Taipei City, Taipei, Taiwan

Urology Centers of Alabama; 🇺🇸 Homewood, Alabama, United States

PI Hospital of Lithuanian University of Health Sciences, Kauno Klinikos; 🇱🇹 Kaunas, Lithuania

AKH Linz GmbH, Department of Urology; 🇦🇹 Linz, Oberösterreich, Austria

PI Klaipėda University Hospital; 🇱🇹 Klaipėda, Lithuania

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Układu Moczowego; 🇵🇱 Warzawa, Poland

Taichung Veteran General Hospital (VGHTC); 🇨🇳 Taichung City, Taichung, Taiwan

"DERMED" Centrum Medyczne Sp. z o.o.; 🇵🇱 Łódź, Poland

Genesis Research, LLC; 🇺🇸 San Diego, California, United States

AdvanceMed Research; 🇺🇸 Lawrenceville, New Jersey, United States

Alliance Research Centers; 🇺🇸 Laguna Hills, California, United States

Carolina Clinical Trials, LLC; 🇺🇸 Concord, North Carolina, United States

Seattle Urology Research Center; 🇺🇸 Burien, Washington, United States

Universitätsklinik für Urologie und Andrologie, Landeskrankenhaus Salzburg (University hospital for Urology and Andrology); 🇦🇹 Salzburg, Austria

Universitätsklinikum RWTH Aachen, Klinik für Urologie; 🇩🇪 Aachen, Nordrhein-Westfalen, Germany

Uniwersyteckie Centrum Kliniczne, Klinika Urologii; 🇵🇱 Gdańsk, Poland

Centralny Szpital Kliniczny MSW w Warszawie, Klinika Urologii i Urologii Onkologicznej; 🇵🇱 Warzawa, Poland

UROCENTRUM MILAB, s.r.o.; 🇸🇰 Prešov, Slovakia

PI Vilnius University Hospital, Santariškių Klinikos; 🇱🇹 Vilnius, Lithuania

Fakultná nemocnica s poliklinikou Žilina Urológia; 🇸🇰 Žilina, Slovakia

Kaohsiung Veteran General Hospital (VGHKS); 🇨🇳 Kaohsiung City, Pingtung, Taiwan

University Hospital Hradec Králové; 🇨🇿 Hradec Králové, Czechia

Thomayerova nemocnice Urologické oddělení; 🇨🇿 Praha, Praha 4 - Krč, Czechia

Chang Gung Memorial Hospital, LinKou (CGMH-LK); 🇨🇳 Taoyuan City, Taiwan

University Hospital Olomouc; 🇨🇿 Olomouc, Czechia